Immune Design (IMDZ) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Immune Design (NASDAQ:IMDZ) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.03, Fidelity Earnings reports. Immune Design had a negative return on equity of 46.95% and a negative net margin of 2,324.21%. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.75 million.

NASDAQ IMDZ traded up $0.03 during trading on Wednesday, hitting $1.52. 964,852 shares of the company traded hands, compared to its average volume of 390,895. Immune Design has a 12 month low of $1.29 and a 12 month high of $5.05. The firm has a market cap of $75.62 million, a P/E ratio of -0.87 and a beta of 2.54.

IMDZ has been the subject of several recent research reports. HC Wainwright set a $8.00 price objective on Immune Design and gave the stock a “buy” rating in a report on Wednesday. Leerink Swann lowered Immune Design from an “outperform” rating to a “market perform” rating in a report on Friday, October 12th. Zacks Investment Research upgraded Immune Design from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Tuesday, October 16th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $11.00 target price on shares of Immune Design in a report on Friday, October 12th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $7.25.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. DRW Securities LLC raised its holdings in Immune Design by 59.2% during the second quarter. DRW Securities LLC now owns 58,900 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 21,900 shares in the last quarter. Bank of America Corp DE raised its holdings in Immune Design by 231.9% during the second quarter. Bank of America Corp DE now owns 46,754 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 32,669 shares in the last quarter. Northern Trust Corp raised its holdings in Immune Design by 11.0% during the second quarter. Northern Trust Corp now owns 357,880 shares of the biotechnology company’s stock valued at $1,628,000 after buying an additional 35,439 shares in the last quarter. Tiverton Asset Management LLC bought a new position in Immune Design during the second quarter valued at about $176,000. Finally, Essex Investment Management Co. LLC bought a new position in Immune Design during the second quarter valued at about $192,000. Institutional investors own 49.36% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/11/07/immune-design-imdz-releases-quarterly-earnings-results-beats-expectations-by-0-03-eps.html.

About Immune Design

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Recommended Story: Yield Curve

Earnings History for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply